Daclizumab Has Winning Efficacy In MS, But Safety Questions Linger
This article was originally published in The Pink Sheet Daily
Executive Summary
Biogen/Abbott multiple sclerosis candidate passed the relapse rate hurdle and showed surprisingly good disability progression data in the Phase II SELECT trial, but there are safety signals that could be a problem.
You may also be interested in...
Keeping Track: FDA Approval Activity Heats Up With Ocaliva, Zinbryta And More
The latest drug development news and highlights from our FDA Performance Tracker.
U.S. Tysabri Labeling Updated With More PML Risk Info But No Reference To JCV Testing
Partners Biogen Idec and Elan had asked both European and U.S. regulators to update the label to include the addition of anti-JC virus antibody status as a risk factor, but so far only the EU has moved toward JCV testing.
Biogen Idec's BG-12 Results Up The Ante In The Oral MS Market
Biogen's drug is poised to become top dog among many oral MS drugs, including Novartis' approved Gilenya, analysts say.